ISSUE 1 · JUNE 2026

Translating what CMS just changed into what it means for your product, your go-to-market, and your investment thesis told from the operator’s chair.

The ISA partners have collectively sat on the buyer’s side of these mandates as health plan executives, health solution operators, health tech investors, and enterprise technology leaders. We’ve signed the contracts, felt the budget pressure, and watched companies succeed or fail based on whether they understood what was changing and why it mattered at the operating level. Each issue of The Signal translates what CMS just changed into what it means for your product, your go-to-market, and your investment thesis. We’ve been through 20+ successful exits valued at over $3 billion in healthtech. We know what a fundable, acquirable company looks like. We know what kills one.

S1 | PRIOR AUTHORIZATION

LIVE CMS-0057-F: PA decision timelines in effect January 1, 2026

JAN 2027 FHIR-based Prior Authorization API compliance deadline

OCT 2027 CMS-0062-P: Drug PA interoperability mandate comment period closes June 15

What happened: As of January 1, 2026, Medicare Advantage plans, Medicaid, CHIP, and qualified health plans must render standard prior authorization decisions within 7 calendar days and urgent decisions within 72 hours. Plans that previously took up to 14 days are now operating under a federal mandate. The FHIR-based API infrastructure requirement follows January 1, 2027. In April 2026, CMS extended this framework to drug prior authorizations for the first time (CMS-0062-P), with final compliance expected by October 2027.

Portfolio companies in prior authorization, clinical decision support, and care coordination are sitting on a regulatory tailwind but only if they’ve built to the FHIR standard. Diligence question to ask every target in this space: Does their product help a payer meet the 7-day standard, or does it depend on the payer having already solved that problem?

S2 | VALUE-BASED CARE

LIVE CMS TEAM Model: 700+ hospitals mandated into episode-based payment, January 1, 2026

What happened: The CMS Transforming Episode Accountability Model (TEAM) launched January 1, 2026, requiring over 700 selected hospitals to manage the total cost and quality of care across five high-volume surgical episodes joint replacement, bypass surgery, hip/femur fracture, spinal fusion, and major bowel procedures from admission through 30 days post-discharge. Top performers earn shared savings. Unprepared organizations face repayment. This is not optional. These hospitals were selected by CMS, not enrolled voluntarily.

The ISA read: Hospital CFOs at TEAM-mandated institutions are now responsible for post-discharge outcomes they have never tracked operationally. That’s not a clinical problem. It’s a data infrastructure and care coordination problem and it creates a defined, urgent enterprise buyer for the right technology.

TEAM-mandated hospitals are under new financial risk starting now. Technology companies supporting episode analytics, post-acute coordination, and 30-day readmission prevention are directly in the critical path of hospital compliance. This is a defined buyer cohort 700+ institutions, identifiable by CMS selection with a documented financial problem.

S3 |  MEDICARE ADVANTAGE

FINALIZED MA Star Ratings overhaul: 11 administrative measures eliminated, clinical outcomes reweighted, April 2026

What happened: CMS finalized a sweeping restructure of the Medicare Advantage Star Ratings methodology in April 2026, eliminating 11 administrative process measures and shifting weight toward clinical outcomes and patient experience. The financial impact is estimated at $18.6 billion redirected across the MA program. Plans that were gaming administrative metrics now face a different optimization target. The 2026-star ratings will directly impact 2027 MA quality bonus payments.

The ISA read: Every MA plan in America just had its report card rewritten. The vendors who were helping plans optimize for the old measures are suddenly less valuable. The vendors who can demonstrably improve clinical outcomes and patient experience metrics are suddenly more valuable. This is a vendor displacement cycle disguised as a regulatory update.

MA plans below 4.0 stars are at higher financial risk than six months ago. Technology vendors that demonstrate a direct line to clinical quality improvement in the remaining star measures are in a strong negotiating position. Ask in diligence: Does this company’s outcome data map to the reweighted MA measures? If yes, the commercial story just got significantly stronger.

The regulatory changes in this issue share a common thread: CMS is accelerating the shift from volume-based to outcome-based accountability, and it is doing so with deadlines and financial consequences not just policy statements.

For Founders, the message is operational: your enterprise buyer’s incentive structure just changed. The product conversations you were having six months ago need to be repriced against what your buyer is now accountable for. The companies that get this right in 2026 will enter their Series B with enterprise contracts that reflect the new buying reality. The ones that don’t will be explaining flat revenue to investors who have read the same CMS press releases you have.

For Investors, the message is underwriting regulatory tailwinds are one of the few durable commercial advantages in healthtech. A company whose product sits directly in the path of a CMS mandate with a defined buyer, a financial consequence, and a compliance deadline is a different investment than a company with a good idea and a long sales cycle. Right now, there are three of those situations active simultaneously. ISA knows which portfolio companies are positioned to benefit, and which are exposed.

1 Founders
Map your product’s value proposition against the three signals above. If none of them creates a new commercial opening for you, that is information worth acting on before your next raise.

2 Investors
Add these three signals to your next portfolio review conversation. Ask each company how the PA mandate, TEAM, and the Star Ratings restructure affect their buyer’s priorities. The answers will tell you more about the team’s market awareness than most diligence documents will.

3 Everyone
Watch the CMS-0062-P comment period, which closes June 15, 2026. The drug PA rule has the same structural impact as the device/service rule and most of the industry is still treating it as a future problem. It isn’t.

Glytec is navigating this exact regulatory moment and ISA is opening the right doors.

One of ISA’s portfolio companies, Glytec the leader in enterprise insulin management is actively helping hospitals comply with the CMS glycemic eCQM mandate that took effect January 1, 2026. Every acute care hospital in the country is now required to report Severe Hypoglycemia and Hyperglycemia eCQMs under the Hospital Inpatient Quality Reporting Program. Hospitals that fail to comply face forfeiture of the full 2.6% annual Medicare reimbursement update. FY2028 payment consequences are already accruing.

ISA has been working alongside Glytec’s leadership to connect them with the hospital executives, CMOs, and quality reporting stakeholders who need this solution most urgently, and at scale. We know which doors to open and how to frame the conversation at the C-suite level, because we’ve sat in those chairs. We’ve signed those contracts. We’ve felt the pressure of those mandates from the other side of the table.

This is not advisory work. This is operators who have been buyers, builders, and sellers more than twenty times, across more than $3 billion in health tech exits actively opening the right doors at the right moment for companies that are ready to walk through them.

We can help you too.

If your company is navigating a CMS mandate, a new quality reporting requirement, or an enterprise buyer relationship that needs a different kind of entry point this is exactly the work ISA does. The three regulatory signals in this issue are not abstractions. They are live commercial opportunities with defined buyers, financial consequences, and deadlines. We know how to position your company inside them.

Want ISA’s read on how these mandates affect your current portfolio or a company you’re evaluating?

Let’s talk before the window closes.